Treatment Refractoriness in Chronic Lymphocytic Leukemia: Old and New Molecular Biomarkers.
Ontology highlight
ABSTRACT: Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. Despite its indolent clinical course, therapy refractoriness and disease progression still represent an unmet clinical need. Before the advent of pathway inhibitors, chemoimmunotherapy (CIT) was the commonest option for CLL treatment and is still widely used in areas with limited access to pathway inhibitors. Several biomarkers of refractoriness to CIT have been highlighted, including the unmutated status of immunoglobulin heavy chain variable genes and genetic lesions of TP53, BIRC3 and NOTCH1. In order to overcome resistance to CIT, targeted pathway inhibitors have become the standard of care for the treatment of CLL, with practice-changing results obtained through the inhibitors of Bruton tyro
SUBMITTER: Maher N
PROVIDER: S-EPMC10299596 | biostudies-literature | 2023 Jun
REPOSITORIES: biostudies-literature
ACCESS DATA